Systemic lupus erythematosus - Activity and outcome;Systemischer lupus erythematodes: Aktivität und outcome

Zeitschrift fur Rheumatologie

Volumn 65, Issue 2, 2006, Pages 103-109

  Aringer, M ^a   Smolen, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Disease activity; Outcome; SLE; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

DEATH; DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; KIDNEY FAILURE; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ARTHRALGIA; DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33645306639     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-006-0040-9     Document Type: Review

References (48)

1. Albrecht J, Taylor L, Berlin JA et al. (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125:889-894
2. Allen E, Farewell VT, Isenberg DA, Gordon C (2005) A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus. Rheumatology (Oxford)
3. American College of Rheumatology (2004) The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 50:3418-3426
4. Aringer M, Smolen JS (2004) TNF and other proinflammatory cytokines in SLE: A rationale for therapeutic intervention. Lupus 13:344-347
5. Aringer M, Smolen JS, Graninger WB (1998) Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 41:414-420
6. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of TNFα blockade in systemic lupus erythematosus - an open label study. Arthritis Rheum 50:3161-3169
7. Balow JE, Austin HA III (2004) Maintenance therapy for lupus nephritis - something old, something new. N Engl J Med 350:1044-1046
8. Bencivelli W, Vitali C, Isenberg DA et al. (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:549-554
9. Bjornadal L, Yin L, Granath F et al. (2004) Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 31:713-719
10. Bombardier C, Gladman DD, Urowitz MB et al. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630-640
11. Boumpas DT, Balow JE (1998) Outcome criteria for lupus nephritis trials: a critical overview. Lupus 7:622-629
12. Buyon JP, Kalunian KC, Ramsey-Goldman R et al. (1999) Assessing disease activity in SLE patients during pregnancy. Lupus 8:677-684
13. Cervera R, Khamashta MA, Font J et al. (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82:299-308
14. Christopher-Stine L, Petri M, Astor BC, Fine D (2004) Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 31:1557-1559
15. Contreras G, Pardo V, Leclercq B et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980
16. Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219-2228
17. Gladman D, Ginzler E, Goldsmith C et al. (1996 a) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363-369
18. Gladman DD, Urowitz MB, Ong A et al. (1996 b) A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 5:190-195
19. Gladman DD, Goldsmith CH, Urowitz MB et al. (2000) The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373-376
20. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288-291
21. Gourley MF, Austin HA, Scott D et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549-557
22. Hay EM, Bacon PA, Gordon C et al. (1993) The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86:447-458
23. Hebert LA, Dillon JJ, Middendorf DF et al. (1995) Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 26:432-438
24. Houssiau FA, Vasconcelos C, D'Cruz D et al. (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131
25. Illei GG, Austin HA, Crane M et al. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248-257
26. Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 50:2048-2065
27. Krupp LB, LaRocca NG, Muir J, Steinberg AD (1990) A study of fatigue in systemic lupus erythematosus. J Rheumatol 17:1450-1452
28. Liang MH, Socher SA, Larson MG, Schur PH (1989) Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118
29. Looney RJ, Anolik JH, Campbell D et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580-2589
30. Moroni G, Quaglini S, Maccario M et al. (1996) "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50:2047-2053
31. Moss KE, loannou Y, Sultan SM et al. (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:409-413
32. Omdal R, Mellgren SI, Koldingsnes W et al. (2002) Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. J Rheumatol 29:482-486
33. Omdal R, Sjoholm H, Koldingsnes W et al. (2005) Fatigue in patients with lupus is not associated with disturbances in cerebral blood flow as detected by SPECT. J Neurol 252:78-83
34. Petri M, Buyon J, Kim M (1999) Classification and definition of major flares in SLE clinical trials. Lupus 8:685-691
35. Ruperto N, Ravelli A, Cuttica R et al. (2005) The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum 52:2854-2864
36. Schett G, Rubin RL, Steiner G et al. (2000) The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 43:420-428
37. Schett G, Smole J, Zimmermann C et al. (2002) The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11:704-715
38. Smolen JS (1987) Clinical and serologic features: Incidence and diagnostic approach. In: Smolen JS, Zielinski CC (eds) Systemic lupus erythematosus. Springer, Berlin Heidelberg New York Tokyo, pp 171-196
39. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945-950
40. Strand V, Gladman D, Isenberg D et al. (1999) Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 26:490-497
41. Strand V, Gladman D, Isenberg D et al. (2000) Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 9:322-327
42. Studnicka-Benke A, Steiner G, Petera P, Smolen JS (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35:1067-1074
43. Stummvoll GH, Aringer M, Smolen JS et al. (2005) IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64:1015-1021
44. Trager J, Ward MM (2001) Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 13:345-351
45. Vitali C, Bencivelli W, Isenberg DA et al. (1992) Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 10:541-547
46. Wang B, Gladman DD, Urowitz MB (1998) Fatigue in lupus is not correlated with disease activity. J Rheumatol 25:892-895
47. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483
48. Wollaston SJ, Farewell VT, Isenberg DA et al. (2004) Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics Group. J Rheumatol 31:2390-2394